Trials / Recruiting
RecruitingNCT07223697
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afimkibart | Afimkibart SC injection will be administered as per the schedule defined in the protocol. |
Timeline
- Start date
- 2026-01-08
- Primary completion
- 2033-02-11
- Completion
- 2033-02-11
- First posted
- 2025-11-03
- Last updated
- 2026-04-13
Locations
7 sites across 3 countries: United States, Canada, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07223697. Inclusion in this directory is not an endorsement.